Myeloperoxidase: A new twist to an old tale

Indian Journal of Clinical Biochemistry

Volumn 27, Issue 2, 2012, Pages 107-109

  Anand, Usha ^a   Anand, C V ^a  

^a PSG INSTITUTE OF MEDICAL SCIENCES AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3 CHLOROTYROSINE; 3 NITROTYROSINE; APOLIPOPROTEIN; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; HYDROGEN PEROXIDE; LOW DENSITY LIPOPROTEIN; METALLOPROTEINASE; MYELOPEROXIDASE; NITRIC OXIDE;

ACUTE HEART INFARCTION; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALZHEIMER DISEASE; ASBESTOSIS; ATHEROSCLEROSIS; CELL DAMAGE; CELL MIGRATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL NEPHRITIS; LUNG INFILTRATE; NEUTROPHIL; NEUTROPHILIA; OXIDATIVE STRESS; REVIEW; THORAX PAIN; VASODILATATION;

EID: 84864462288     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-012-0220-0     Document Type: Review

References (25)

1. Iyer GYN, Islam DMF, Quastel JH. Biochemical aspects of phagocytosis. Nature. 1961;192:535-41.
2. Klebenoff SJ. Myeloperoxidase. Friend and Foe. J Leukoc Biol. 2005;77:598-625.
3. Prutz WA. Hypochlorous acid interactions with thiols, nucleo-tides, DNA and other biological substrates. Arch Biochem Bio-phys. 1996;332:110-20.
4. Kinkade JM Jr, Pember SO, Barnes KC, Shapira R, Spitznagel JK, Martin LE. Differential distribution of distinct forms of myeloperoxidase in different azurophilic granule subpopulation from human neutrophils. Biochem Biophys Res Commun. 1983;114:296-303.
5. Fiedler TJ, Davey CA, Fenna RE. X-ray crystal structure and characterization of halide-binding sites of human myeloperoxi-dase at 1.8 A resolution. J Biol Chem. 2000;275:11964-71.
6. Klebenoff SJ. Myeloperoxidase. Proc Assoc Am Physicians. 1999;111:383-9.
7. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with CAD syndromes. Circulation. 2003;108:1440-5.
8. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-42.
9. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-604.
10. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers and cardiovascular risk assessment. 2003;14:353-9.
11. Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Me-hilli J, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J. 2008;155:356-60.
12. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloper-oxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529-41.
13. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075-81.
14. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275: 37524-32.
15. Rossi A, Franceschini L, Fusaro M, Cicoira M, Eleas AA, Golia G, et al. Carotid atherosclerotic plaque instability in patients with acute myocardial infarction. Int J Cardiol. 2006;111:263-6.
16. Johnson KJ, Fantone JCI, Kaplan J, Ward PA. In vivo damage of rat lungs by oxygen metabolites. J Clin Invest. 1981;67:983-93.
17. Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987;79:1665-73.
18. Buss IH, Darlow BA, Winterbourn CC. Elevated protein car-bonyls and lipid peroxidation products correlating with myelo-peroxidase in tracheal aspirates from premature infants. Pediatr Res. 2000;47:640-5.
19. Haegens A, Heeringa P, Jan van Suylen R, Steele C, Aratani Y, O'Donoghue RJJ, et al. J Immunol. 2009;182:7990-6.
20. Barczyk A, Sozanska E, Trzaska M, Pierzchala W. Decreased levels of myeloperoxidase in induced sputum of patients with COPD after treatment with oral glucocorticoids. Chest. 2004;126: 389-93.
21. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, et al. Myeloperoxidase polymorphism is associated with gender-specific risk for Alzheimer's disease. Exp Neurol. 1999;155:31-41.
22. Jolivalt C, Leininger-Muller B, Bertrand P, Herber R, Christen Y, Siest G. Differential oxidation of apo-E isoforms and interaction with phospholipids. Free Rad Biol Med. 1996;28:129-40.
23. Malle E, Buch T, Grone HJ. Myeloperoxidase in kidney disease. Kidney Int. 2003;64:1956-67.
24. Madhusudhana Rao A, Anand Usha, Anand CV. Meyloperoxi-dase in chronic kidney disease. Ind J Clin Biochem. 2011;26: 28-31.
25. Madhusudhana Rao A, Apoorva R, Usha A, Anand CV, Venu G. Effect of hemodialysis on plasma myeloperoxidase activity in end stage renal disease patients. Ind J Clin Biochem. doi:10.1007/s12291-012-0194-y.